Overview
Top Medical Research Studies
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Key predictors included a history of thromboembolism and bleeding, low time in therapeutic range, and reduced kidney function. Notably, while VKAs are crucial, they come with risks that we need to monitor closely to improve patient outcomes.
Most Useful Reviews
Medical Researches
- All Researches
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
In our analysis of a randomized clinical trial, we compared apixaban, a novel anticoagulant, to vitamin K antagonists and evaluated the overall safety and efficiency of these treatments.
Our results showed that apixaban effectively reduced major bleeding events without increasing ischemic risks compared to vitamin K. We recommend using apixaban with a low-potency P2Y inhibitor as the standard care approach.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
User Reviews
- All Reviews
- Positive Reviews
- Negative Reviews
Frequently Asked Questions
A blood clot is a mass of blood that changes from a liquid to a gel, effectively forming a plug that can stop bleeding. This natural process, known as coagulation, is critical for preventing excessive blood loss when you sustain an injury. Blood clots can occur in various areas of the body, typically at the site of a wound, but they can also form within blood vessels without an obvious injury, which may lead to serious health complications.
While blood clots are essential for healing, they can pose significant health risks if they form inappropriately. For example, a deep vein thrombosis (DVT) occurs when a clot forms in a deep vein, usually in the legs, and can travel to the lungs, causing a life-threatening condition called a pulmonary embolism. Risk factors for blood clots include prolonged immobility, certain medical conditions, and the use of specific medications, among others. It’s important to recognize the symptoms of abnormal clotting, such as swelling, pain, and redness in the affected area, and seek medical attention if they occur.
Vitamin K is a fat-soluble vitamin crucial for various bodily functions, particularly in the clotting process of blood. It exists in two primary forms: K1 (phylloquinone), which is primarily found in leafy green vegetables like spinach and kale, and K2 (menaquinone), which is found in fermented foods and certain animal products. Vitamin K plays a significant role in the synthesis of proteins that regulate blood coagulation and is also essential for bone metabolism, assisting in the binding of calcium to bones and other tissues.
Deficiencies in vitamin K can lead to increased bleeding and bruising, and in severe cases, it may contribute to bone weakness. While most people can obtain adequate amounts of vitamin K through a balanced diet rich in vegetables and fermented foods, those with certain medical conditions or who are on specific medications may require monitoring and supplementation. Incorporating a variety of nutrient-dense foods into your diet is the best way to ensure you get enough vitamin K for optimal health.
Vitamin K plays a crucial role in the body's blood clotting process, making it essential for maintaining proper vascular health. It supports the synthesis of certain proteins known as clotting factors, which are vital for blood coagulation. When an injury occurs, these proteins help form a clot to stop bleeding. Thus, an adequate intake of Vitamin K can be beneficial in situations where blood clotting needs to occur, like in response to a wound or surgery.
However, it's important to note that while Vitamin K is essential for normal clotting, it should be approached cautiously, especially for individuals on anticoagulant medications (like warfarin), which work by inhibiting Vitamin K's action. If you are considering changes to your Vitamin K intake or have concerns regarding blood clotting, it is always advisable to consult a healthcare professional for tailored advice.
Based on user reviews, the timeframe for seeing results from vitamin K2 supplementation varies among individuals but generally falls within a few weeks to a couple of months. For instance, one user reported that after two months of taking vitamin K2, their blood clotting improved significantly, returning to normal levels after experiencing difficulties previously (Read Review). Similarly, another user mentioned a drastic reduction in severe period clots after starting vitamin K2, indicating noticeable changes within a relatively short period (Read Review).
However, some users have indicated that consistent use over time is essential for optimal benefits. One user stated they had completed three bottles of the supplement and were hopeful for positive results at their next medical check-up (Read Review). Overall, while many users experience initial improvements within weeks to months, maintaining supplementation and patience might be key for long-term benefits, particularly in managing blood clotting and associated conditions.
The scientific research supports the use of certain supplements, particularly vitamin K antagonists (VKAs), for blood clot management. A variety of studies highlight their effectiveness in treating conditions that predispose patients to thrombus formation, such as left ventricular thrombosis and antiphospholipid syndrome. For example, one multicenter study demonstrated that about 70% of patients treated with VKAs saw their blood clots resolve, indicating significant therapeutic potential [2]. Additionally, VKAs like warfarin have shown proficiency in reversing the effects of anticoagulants and promoting clot formation [1].
In comparative studies, VKAs were often matched against newer medications, revealing a mixed landscape of efficacy and safety. For instance, direct oral anticoagulants (DOACs) and VKAs exhibited similar rates of major bleeding and recurrent clots, suggesting both have valid roles in treatment [5]. Moreover, NOACs, which may offer better outcomes in some scenarios, are becoming more favorable, as evidenced by a review that reported they could achieve a higher rate of clot resolution than VKAs without significantly increasing the risk of adverse events [11]. Overall, while research indicates that VKAs are supported in specific contexts, the growing body of evidence around new oral anticoagulants suggests a shift in clinical preference towards these newer therapies for safer and more effective management of blood clots.
Based on user reviews, individuals have reported various improvements in their symptoms after taking vitamin K2. Many users specifically highlight its effectiveness in addressing blood clotting issues. One user mentioned that after two months of supplementation, their previously poor blood clotting condition returned to normal (Read Review). Similarly, another user shared that vitamin K2 drastically reduced severe period clots, allowing them to go out without fear (Read Review). Additionally, several reviews suggest that combining vitamin K2 with vitamin D3 enhances its positive effects on calcium metabolism and overall health, further supporting the regulation of blood clotting (Read Review)(Read Review).
Moreover, users have noted benefits such as improved bone strength, which can be attributed to K2’s role in directing calcium to bones instead of soft tissues or arteries. One individual shared that over time, they have experienced an increase in the strength of their jaw and teeth while managing calcium effectively in their body (Read Review). Overall, while many users report positive outcomes ranging from improved blood clotting to enhanced bone health, it is important to recognize that individual results can vary.
Based on user reviews, many individuals report that combining vitamin K2 with vitamin D3 enhances its effectiveness in managing blood clotting and overall health. Users have noted that this combination allows for better calcium absorption and directed usage, preventing calcium buildup in arteries while strengthening bones. For example, one user shared their experience of taking K2 alongside D3, emphasizing how they feel energized and attribute improvements in their health to this regimen (Read Review). Another noted that these vitamins together balance and regulate blood clotting effectively, illustrating the synergy between K2 and D3 in promoting vascular health (Read Review).
Moreover, several reviews highlight the importance of considering vitamin K2 in conjunction with other vitamins and minerals for optimal results. Users have found that taking K2 with magnesium, for instance, not only supports blood vessel health but also ensures proper calcium distribution throughout the body (Read Review). Additionally, one review advises that to maximize the efficiency of these supplements, they should be taken separately from one another, suggesting a rather meticulous approach to supplementation (Read Review). Overall, the consensus among users is that when paired thoughtfully, vitamin K2 and other supplements can significantly impact blood clot management and overall health.
Based on user reviews, many individuals report positive experiences with specific dosages of Vitamin K2 for treating blood clot issues. A common recommendation observed is the daily intake of one capsule, which some users have found to be effective for their concerns related to blood clotting and metabolic processes. For instance, one user noted, "the recommended dose is one capsule daily" and emphasized the benefits they experienced from consistent usage (Read Review). Another user shared that after starting on Vitamin K2, their severe period clots drastically reduced after taking it daily (Read Review).
Moreover, users highlight the synergistic effect of combining Vitamin K2 with Vitamin D3, often suggesting that this combination enhances the functionality of both supplements and aids in calcium regulation, thereby supporting overall vascular health and preventing the risk of calcium buildup in soft tissues. As one user mentioned, "It's crucial to take K2 separately from Vitamin D3 for optimal results" (Read Review). Overall, while individual needs may vary, a daily dosage of Vitamin K2 appears to be a common effective strategy among users for addressing blood clotting concerns.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
With over 600 patients involved, we observed that only a small percentage experienced these adverse outcomes within six months. Thus, both DOACs and VKAs appear to be valid choices for treating this condition, offering new insights into patient care.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
References
- Karkouti K, Gareis M, Li C, Brandstätter H, Pichotta A, et al. Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative review. Transfus Apher Sci. 2025;64:104115. doi:10.1016/j.transci.2025.104115
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. doi:10.1007/s11739-025-03922-6
- Geertsema-Hoeve BC, Radin M, Sciascia S, Urbanus RT, Huisman A, et al. Problem Solved? An Individual Ratio between Point-of-Care and Venous International Normalized Ratio Values in Two Patients with Antiphospholipid Syndrome: Two Case Reports. TH Open. 2025;9:a25425358. doi:10.1055/a-2542-5358
- Last J, Birschmann I, Lindau S, Konstantinides S, Grottke O, et al. Anticoagulant Management After Emergency Surgery or Major Bleeding in Anticoagulated Patients-Results of the Prospective RADOA Registry. Pharmaceuticals (Basel). 2025;18. doi:10.3390/ph18020170
- van de Munckhof A, van Kammen MS, Tatlisumak T, Krzywicka K, Aaron S, et al. Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study. Lancet Neurol. 2025;24:199. doi:10.1016/S1474-4422(24)00519-2
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. doi:10.36660/abc.20240147
- Hall EH, Sølsnes MH, Sandberg S, Sølvik UØ. Patient self-management of warfarin therapy - a long-term follow up study. Thromb J. 2025;23:14. doi:10.1186/s12959-025-00694-z
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. doi:10.1007/s11239-025-03067-5
- Tannu M, Lopes RD, Wojdyla DM, Goodman SG, Aronson R, et al. Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS. J Am Coll Cardiol. 2025;85:1157. doi:10.1016/j.jacc.2024.10.125
- Zorman MJ, Vibhishanan J, Dangas K, Castle J, Li KHC, et al. Valve Thrombosis and Antithrombotic Therapy After Bioprosthetic Mitral Valve Replacement: A Systematic Review And Meta-Analysis. Eur Heart J Cardiovasc Pharmacother. 2025. doi:10.1093/ehjcvp/pvaf005
- Mo GL, Wen J, Ye YY, Lu YQ, Gan TM, et al. Efficacy and Safety of New Oral Anticoagulants versus Warfarin in the Resolution of Atrial Fibrillation with Left Atrial/Left Atrial Appendage Thrombus: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med. 2025;26:26055. doi:10.31083/RCM26055
- Kempers EK, Visser C, Geijteman ECT, Goedegebuur J, Portielje JEA, et al. Discontinuation of Anticoagulants and Occurrence of Bleeding and Thromboembolic Events in Vitamin K Antagonist Users with a Life-limiting Disease. Thromb Haemost. 2025. doi:10.1055/a-2524-5334
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. doi:10.1136/openhrt-2024-002966
- Mapelli M, Celeste F, Maiolo G, Mancini E, Agostoni P. Incidental Diagnosis of Massive Mobile Left Ventricle Thrombi Following COVID-19 in a Heart Failure Patient. JACC Case Rep. 2024;29:102870. doi:10.1016/j.jaccas.2024.102870
- Gustafsson F, Uriel N, Netuka I, Katz JN, Pagani FD, et al. Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial. JAMA Cardiol. 2025;10:235. doi:10.1001/jamacardio.2024.4849
- Premkumar M, Bhujade H, Sharma P, Nain J, Ahluwalia J, et al. Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival. Aliment Pharmacol Ther. 2025;61:971. doi:10.1111/apt.18474
